Characterizing and understanding body weight patterns in patients treated with pregabalin
Javier Cabrera1, Birol Emir, Diana Dills
1Rutgers University, Piscataway, NJ, USA.
Current Medical Research and Opinion
|April 13, 2012
Summary
Most patients on pregabalin maintained weight within 7% of baseline. However, about one in six experienced significant weight gain, particularly early in treatment.
Area of Science:
- Pharmacology
- Clinical Medicine
- Weight Management
Background:
- Pregabalin is widely prescribed for various neurological conditions.
- Weight change is a known potential side effect of pregabalin therapy.
- Understanding weight change patterns is crucial for patient management.
Purpose of the Study:
- To analyze weight change patterns in patients treated with pregabalin over one year.
- To identify distinct patient subgroups based on weight fluctuations during pregabalin therapy.
- To correlate weight change patterns with baseline characteristics and treatment duration.
Main Methods:
- Pooled data analysis from 106 studies involving 43,525 patients.
- Development of seven distinct weight change patterns.
- Exploratory 'change point' analyses to determine when weight trends shifted.
- Assessment of weight change patterns relative to baseline weight and BMI.
Main Results:
- 81.8% of patients maintained weight within ±7% of baseline ('Pattern 4').
- 14.5% were 'delayed weight gainers' and 2.6% were 'early weight gainers'.
- Weight gainers had lower average baseline weight/BMI and experienced median weight increases of 9.12% and 13.9% respectively.
Conclusions:
- The majority of patients on pregabalin (150-600 mg/day) maintain weight within ±7% of baseline over one year.
- Approximately 16.7% of patients experience clinically significant weight gain (≥7%) within 2-12 months of treatment.
- Individualized monitoring for weight changes is recommended during pregabalin therapy.
Related Concept Videos
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:29Assessment of the Gastrointestinal System II: Health Perception Pattern
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health Perception Patterns
Health perception patterns offer valuable insights into a patient's lifestyle habits and how they may impact their GI health. These patterns include:
Health Perception Patterns
Health perception patterns offer valuable insights into a patient's lifestyle habits and how they may impact their GI health. These patterns include:
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...